2B70.DE vs. LYPE.DE
2B70.DE (iShares Nasdaq US Biotechnology UCITS ETF) and LYPE.DE (Amundi MSCI World Health Care UCITS ETF EUR Acc) are both Health & Biotech Equities funds - 2B70.DE tracks the Nasdaq Biotechnology while LYPE.DE tracks the MSCI World Health Care. Both are passively managed. Over the past 5 years, 2B70.DE returned 5.68%/yr vs 5.27%/yr for LYPE.DE. A 0.72 correlation means they provide meaningful diversification when combined. 2B70.DE charges 0.35%/yr vs 0.30%/yr for LYPE.DE.
Performance
2B70.DE vs. LYPE.DE - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, 2B70.DE achieves a 4.53% return, which is significantly higher than LYPE.DE's -2.00% return.
2B70.DE
- 1D
- 3.29%
- 1M
- 0.58%
- YTD
- 4.53%
- 6M
- 4.05%
- 1Y
- 39.50%
- 3Y*
- 10.00%
- 5Y*
- 5.68%
- 10Y*
- —
LYPE.DE
- 1D
- 2.79%
- 1M
- 3.83%
- YTD
- -2.00%
- 6M
- -1.54%
- 1Y
- 9.49%
- 3Y*
- 2.46%
- 5Y*
- 5.27%
- 10Y*
- 7.45%
2B70.DE vs. LYPE.DE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
2B70.DE iShares Nasdaq US Biotechnology UCITS ETF | 4.53% | 18.62% | 4.60% | 2.56% | -6.29% | 7.59% | 14.52% | 30.18% | -7.35% | 2.65% |
LYPE.DE Amundi MSCI World Health Care UCITS ETF EUR Acc | -2.00% | 2.17% | 7.03% | -0.27% | -0.17% | 30.38% | 2.44% | 27.39% | 5.67% | 0.97% |
Correlation
The correlation between 2B70.DE and LYPE.DE is 0.71, which is moderate. They share some common price drivers but move independently often enough to provide real diversification benefit when combined.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.71 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.65 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.68 |
Correlation (All Time) Calculated using the full available price history since Nov 24, 2017 | 0.72 |
The correlation between 2B70.DE and LYPE.DE has been stable across timeframes, ranging from 0.65 to 0.72 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
2B70.DE vs. LYPE.DE — Risk / Return Rank
2B70.DE
LYPE.DE
2B70.DE vs. LYPE.DE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq US Biotechnology UCITS ETF (2B70.DE) and Amundi MSCI World Health Care UCITS ETF EUR Acc (LYPE.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| 2B70.DE | LYPE.DE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.36 | ||
| Sortino ratioReturn per unit of downside risk | +1.76 | ||
| Omega ratioGain probability vs. loss probability | 1.34 | 1.13 | +0.21 |
| Calmar ratioReturn relative to maximum drawdown | 6.15 | 0.93 | +5.23 |
| Martin ratioReturn relative to average drawdown | 17.06 | 2.27 | +14.79 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| 2B70.DE | LYPE.DE | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 2.04 | 0.68 | +1.36 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.28 | 0.39 | -0.11 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.51 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.36 | 0.76 | -0.40 |
Drawdowns
2B70.DE vs. LYPE.DE - Drawdown Comparison
The maximum 2B70.DE drawdown since its inception was -30.87%, which is greater than LYPE.DE's maximum drawdown of -25.95%. Use the drawdown chart below to compare losses from any high point for 2B70.DE and LYPE.DE.
Loading charts...
Drawdown Indicators
| 2B70.DE | LYPE.DE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -30.87% | -25.95% | -4.92% |
Max Drawdown (1Y)Largest decline over 1 year | -6.33% | -10.21% | +3.88% |
Max Drawdown (3Y)Largest decline over 3 years | -29.34% | -21.30% | -8.04% |
Max Drawdown (5Y)Largest decline over 5 years | -30.87% | -21.30% | -9.57% |
Max Drawdown (10Y)Largest decline over 10 years | — | -25.95% | — |
Current DrawdownCurrent decline from peak | -1.26% | -8.75% | +7.49% |
Average DrawdownAverage peak-to-trough decline | -10.01% | -5.06% | -4.95% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.29% | 4.18% | -1.89% |
Volatility
2B70.DE vs. LYPE.DE - Volatility Comparison
iShares Nasdaq US Biotechnology UCITS ETF (2B70.DE) has a higher volatility of 6.65% compared to Amundi MSCI World Health Care UCITS ETF EUR Acc (LYPE.DE) at 4.96%. This indicates that 2B70.DE's price experiences larger fluctuations and is considered to be riskier than LYPE.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| 2B70.DE | LYPE.DE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.65% | 4.96% | +1.69% |
Volatility (6M)Calculated over the trailing 6-month period | 14.26% | 9.76% | +4.50% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.09% | 13.82% | +5.27% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 20.34% | 13.41% | +6.93% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 21.76% | 14.64% | +7.12% |
2B70.DE vs. LYPE.DE - Expense Ratio Comparison
2B70.DE has a 0.35% expense ratio, which is higher than LYPE.DE's 0.30% expense ratio.
Dividends
2B70.DE vs. LYPE.DE - Dividend Comparison
Neither 2B70.DE nor LYPE.DE has paid dividends to shareholders.
Frequently Asked Questions
2B70.DE and LYPE.DE have a correlation of 0.71, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
On fees, LYPE.DE is cheaper at 0.30% per year. The better choice depends on whether you care most about return, fees, risk, or income.
LYPE.DE is cheaper with a 0.30% expense ratio, compared with 0.35% for 2B70.DE.
2B70.DE tracks Nasdaq Biotechnology, while LYPE.DE tracks MSCI World Health Care. They also come from different issuers: iShares and Amundi. Their fees differ too: 0.35% for 2B70.DE and 0.30% for LYPE.DE.
Find the right allocation for 2B70.DE and LYPE.DE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer